2型糖尿病患者合并代谢相关脂肪性肝病肝纤维化标志物研究  

Study on markers of liver fibrosis in type 2 diabetes mellitus with metabolic associated fatty liver disease combined

作　　者：黄秀婷 张秀英[1] 李玉凤 周翔海[1] 韩学尧[1] 纪立农[1] HUANG Xiuting;ZHANG Xiuying;LI Yufeng(Department of Endocrinology,Peking University People’s Hospital,Beijing 100044,China)

机构地区：[1]北京大学人民医院内分泌科,100044 [2]北京市平谷区人民医院内分泌科

出　　处：《中国糖尿病杂志》2022年第5期337-342,共6页Chinese Journal of Diabetes

摘　　要：目的 比较正常人群、代谢相关脂肪性肝病(MAFLD)患者、T2DM合并MAFLD患者的肝纤维化标志物水平,探讨其临床意义。方法 选取2013年6月至2014年9月于北京平谷地区采用随机分层抽样法进行代谢性疾病调查的893名受试者,分为正常对照(NC)组235名,单纯MAFLD组452例,T2DM合并MAFLD组(T2DM+MAFLD)206例,检测各组生化指标、Ⅲ型前胶原(PCⅢ)和透明质酸(HA)肝纤维化因子水平。结果 血清PCⅢ及HA水平MAFLD组高于NC组[6.10(4.07,8.33)vs 4.09(2.95,5.95)μg/L,P<0.001]、[62.59(43.93,86.08)vs 51.66(37.04,74.24)μg/L,P=0.002],T2DM+MAFLD组高于MAFLD组[6.75(4.98,8.92)vs 6.10(4.07,8.33)μg/L,P=0.01]、[67.78(46.89,98.80)vs 62.59(43.93,86.08)μg/L,P=0.018]。结论 MAFLD患者血清PCⅢ及HA水平较正常对照人群升高,T2DM合并MAFLD患者更高。T2DM可能加重肝纤维化程度,血清PCⅢ及HA测定有助于T2DM合并MAFLD患者早期预测和干预肝纤维化。Objective diabetes mellitus(T2DM)and/or metabolic associated fatty liver disease(MAFLD)and their clinical significance.investigate metabolic diseases.A total of 893 subjects were included in the study and divided into three groups:normal control group(NC,n=235),MAFLD group(n=452),and T2DM with MAFLD group(n=206).Fasting blood biochemical parameters and serum levels of procollagen type Ⅲ(PCⅢ)and hyaluronic acid(HA)quantification kits were used to test the levels of liver fibrosis factors in all the subjects.The clinical features and difference in fibrotic biomarkers were analyzed among the groups,all statistical analyzes were done using SPSS software.levels among the three groups.The levels of serum PCⅢ and HA were higher in MAFLD group than in NC group[6.10(4.07,8.33)vs 4.09(2.95,5.95)μg/L,P<0.001],[62.59(43.93,86.08)vs 51.66(37.04,74.24)μg/L,P=0.002].The levels of PCⅢ and HA were much higher in the T2DM combined with MAFLD group[6.75(4.98,8.92)vs 6.10(4.07,8.33)μg/L,P=0.01],[67.78(46.89,98.80)vs 62.59(43.93,86.08)μg/L,P=0.018].group,especially in T2DM with MAFLD group.T2DM aggravated the level of hepatic fibrosis.The determination of serum PCIII and HA contributed to the early prediction and intervention of T2DM with MAFLD.

关 键 词：糖尿病 2型 代谢相关脂肪性肝病 Ⅲ型前胶原 透明质酸 

分 类 号：R575[医药卫生—消化系统] R587.1[医药卫生—内科学]